Is NCT06431594 recruiting in Orlando, FL?

Yes, NCT06431594 is currently recruiting participants at its Orlando, FL location. This solid tumors clinical trial is actively enrolling qualified participants.

How do I join the solid tumors clinical trial in Orlando?

To join this clinical trial in Orlando, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Orlando clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Solid Tumors Clinical Trial in Orlando, FL

Who Can Participate

Inclusion Criteria

Males or females aged 18 years or older (≥18 years).

Participants with pathologically confirmed advanced solid tumor (who have failed or are intolerant to standard of care.

PROC cohort

Histologically documented, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer.

Must have received or are intolerant to 1 but no more than 4 lines of prior systemic therapy.

Platinum-resistant disease, defined as progression or relapse within 6 months after the completion of platinum-based therapy.

Must have had prior bevacizumab , unless there is a documented contraindication or intolerance.

Participants with known Folate receptor-α (FR-α) expressing tumors must have received mirvetuximab soravtansine if the regimen is locally available, unless there is a documented contraindication or intolerance. Participants with known Breast cancer susceptibility gene (BRCA) mutated tumors should have received a Poly adenosine diphosphate-ribose polymerase (PARP) inhibitor if the regimen is locally available, unless there is a documented contraindication or intolerance.

Endometrial cancer cohort

Histologically documented, advanced (metastatic and/or unresectable) or recurrent endometrial cancer.

Must have received or are intolerant to 1 but no more than 4 lines of prior systemic therapy.

Must have had prior platinum and PD(L)-1 inhibitor (in same regimen or in separate regimens), if the regimen is locally available, unless there is a documented contradiction or intolerance

All epithelial histologies are permitted including carcinosarcoma.

Participants have at least one target lesion as assessed per the RECIST 1.1

Tumor tissue from a newly obtained biopsy or archival tumor tissue is required for retrospective detection of B7 homolog 4 (B7-H4) expression by IHC in central laboratory and other biomarker analysis. Tissue from a newly obtained biopsy is preferred. If a newly obtained biopsy is not feasible, archival tumor tissue within 2 years prior to the first dose of study drug is acceptable.

Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2 and no deterioration within 2 weeks before the first dose.

Have a life expectancy of at least 12 weeks.

Exclusion Criteria

Have received any B7-H4-targeted therapy

Have received any of cytotoxic chemotherapy drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 28 days prior to the first dose of study drug; or need to continue these drugs during the study.

Have received locoregional radiation therapy within 2 weeks prior to the first dose of study drug; more than 30% of bone marrow irradiation or wide-field radiation therapy within 4 weeks prior to the first dose of study treatment.

Presence of pleural/abdominal effusion/ascites requiring clinical intervention; presence of pericardial effusion

Major surgery within 28 days prior to the first dose of study treatment.

Evidence of brain metastasis unless asymptomatic;

Has inadequate bone marrow reserve or hepatic/renal functions .

Mean Fridericia-corrected QT interval (QTcF) QTcF \>450 msec or QTcF \>480 msec for participants with bundle branch blocK;

Evidence of current clinically significant arrhythmias or ECG abnormalities

Left ventricular ejection fraction (LVEF) \< 50%.

Have severe, uncontrolled or active cardiovascular disorders, serious or poorly controlled hypertension, clinically significant bleeding symptoms or serious arteriovenous thromboembolic events

Has current active pneumonitis/ILD or any history of ILD, any history of pneumonitis requiring steroids or immunomodulatory treatment within 90 days of planned randomization/enrollment or any history of drug-induced pneumonitis/ILD.Have received prior therapy with topoisomerase inhibitors or topoisomerase inhibitor Antibody-drug conjugate (ADCs)

Primary platinum refractory disease defined as those who have progressed on or within 12 weeks of last dose of first line platinum therapy not permitted.

Non-epithelial carcinoma, clear-cell, mucinous, germ-cell, low-grade serous, or low-grade endometrioid carcinoma not permitted.

Endometrial cancer a. Mesenchymal tumors of the uterus (uterine sarcomas) not permitted.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orlando?

Yes, this clinical trial (NCT06431594) has an active research site in Orlando, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumors Treatment Options in Orlando, FL

If you're searching for solid tumors treatment options in Orlando, FL, this clinical trial (NCT06431594) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orlando research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumors clinical trials near you to find additional studies recruiting in your area.

Solid Tumors Clinical Trial in Orlando, FL

Expert Care in Orlando

IRB Approved

No-Cost Care

Apply for This Orlando Location

Why Participate?

Simple Process

About This Solid Tumors Study in Orlando